ICH Q8 Pharmaceutical Development
E131967
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
All labels observed (2)
| Label | Occurrences |
|---|---|
| ICH Q8 Pharmaceutical Development canonical | 6 |
| ICH Q8 | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1151204 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: ICH Q8 Pharmaceutical Development Context triple: [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, notableWork, ICH Q8 Pharmaceutical Development]
-
A.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
ISO 14971
ISO 14971 is an international standard that specifies a systematic process for risk management of medical devices throughout their life cycle.
-
D.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
E.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: ICH Q8 Pharmaceutical Development Target entity description: ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
A.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
ISO 14971
ISO 14971 is an international standard that specifies a systematic process for risk management of medical devices throughout their life cycle.
-
D.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
E.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
ICH quality guideline
ⓘ
pharmaceutical guideline ⓘ regulatory guidance document ⓘ |
| aimsTo |
improve product quality consistency
ⓘ
reduce manufacturing variability ⓘ |
| appliesTo |
marketing authorization applications
ⓘ
new drug applications ⓘ pharmaceutical products for human use ⓘ |
| documentType | harmonised tripartite guideline ⓘ |
| emphasizes |
risk-based development
ⓘ
science-based development ⓘ systematic approach to development ⓘ |
| encourages |
use of design of experiments
ⓘ
use of prior knowledge in development ⓘ use of risk management tools ⓘ |
| focusesOn |
pharmaceutical development
ⓘ
process development ⓘ product development ⓘ |
| formsPartOf | ICH quality by design framework ⓘ |
| guides |
establishment of control strategy
ⓘ
selection of formulation components ⓘ selection of manufacturing process ⓘ |
| hasAbbreviation |
ICH Q8 Pharmaceutical Development
self-linksurface differs
ⓘ
surface form:
ICH Q8
|
| hasSection |
compatibility of drug product with diluents or co-administered products
ⓘ
container closure system ⓘ drug product development ⓘ manufacturing process development ⓘ microbiological attributes ⓘ pharmaceutical development report ⓘ |
| introducesConcept |
control strategy
ⓘ
critical process parameters ⓘ critical quality attributes ⓘ design space ⓘ |
| issuedBy | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ⓘ |
| objective |
to enhance understanding of product and process
ⓘ
to facilitate more flexible regulatory approaches ⓘ |
| partOf |
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ⓘ
surface form:
International Council for Harmonisation quality guidelines
|
| regionImplementedIn |
European Union
ⓘ
Japan ⓘ United States of America ⓘ
surface form:
United States
|
| relatedTo |
ICH Q10 Pharmaceutical Quality System
ⓘ
ICH Q11 Development and Manufacture of Drug Substances ⓘ ICH Q9 Quality Risk Management ⓘ |
| scopeIncludes |
biotechnological/biological products
ⓘ
chemical drug products ⓘ |
| supports | lifecycle management of pharmaceutical products ⓘ |
| supportsConcept | quality by design ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: ICH Q8 Pharmaceutical Development Description of subject: ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
Referenced by (7)
Full triples — surface form annotated when it differs from this entity's canonical label.